1. Home
  2. PHAT

as of 02-09-2026 2:55pm EST

$12.99
+$0.41
+3.26%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Founded: 2018 Country:
United States
United States
Employees: N/A City: FLORHAM PARK
Market Cap: 1.1B IPO Year: 2019
Target Price: $17.33 AVG Volume (30 days): 1.1M
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.80 EPS Growth: N/A
52 Week Low/High: $2.21 - $18.31 Next Earning Date: 03-05-2026
Revenue: $147,190,000 Revenue Growth: 460.30%
Revenue Growth (this year): 221.87% Revenue Growth (next year): 80.37%
P/E Ratio: N/A Index: N/A
Free Cash Flow: -225377000.0 FCF Growth: N/A

AI-Powered PHAT Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 20 hours ago

AI Recommendation

hold
Model Accuracy: 75.66%
75.66%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Phathom Pharmaceuticals Inc. News

PHAT Breaking Stock News: Dive into PHAT Ticker-Specific Updates for Smart Investing

All PHAT News

Share on Social Networks: